Dr Paul Sargos (Institut Bergonié, France) presented the first results of the GETUG-AFU 22 study and won the second prize in the EAU20 Best Abstract Awards Oncology .
The multicentre, randomised, phase 2 GETUG-AFU 22 study, compared 6 months of degarelix short-term androgen deprivation therapy (ADT) in combination with radiotherapy and radiotherapy alone as salvage treatment for patients with detectable prostate-specific antigen (PSA) levels after radical prostatectomy (RP). The primary efficacy endpoint was event-free survival, which will be reported later this year. Key secondary endpoints were toxicity (as measured by CTCAE V4.0) and quality of life (QLQ-C30 and QLQ-PR25) results.
Dr Sargos presented the key secondary endpoints in 125 patients with localised prostate cancer, treated by RP, with a PSA level post-RP ≥0.2 ng/mL and ≤2 ng/mL at randomisation and N0 M0 on imaging. Median PSA level was 0.3 ng/mL (0.09-1.82) post-RP and 0.6 ng/mL (0.12-3.65) at randomisation.
With a median follow-up of 38 months, the 2-year toxicity showed no differences in late genitourinary or gastrointestinal toxicity between the 2 arms (P=0.145). No difference was seen between the 2 arms for erectile dysfunction, 2 patients in each arm reported cardiovascular events of grade 3 (in the radiotherapy-alone arm: tight coronary stenosis and femoral arteritis; in the radiotherapy + short-term ADT arm: pulmonary embolism and cardiac arrhythmia). The number of second cancers was not significantly different between the arms.
Quality of life was evaluated at 24 months in 59% of patients in the radiotherapy arm and 77% in the radiotherapy plus short-term ADT arm. At 12 months, QLQ-PR25-related symptoms were significantly higher in the radiotherapy plus short-term ADT arm (P=0.04), but these data normalised by 24 months, when no significant difference in QLQ-C30 or QLQ-PR25 outcomes was reported. This study highlights the good tolerance of post-operative radiotherapy with or without short-term ADT.
- Sargos P, et al. EAU20 Virtual Congress, 17-26 July 2020, Abstract PT925.
« Reduced BCG frequency, faster NMIBC recurrence Next Article
Targeting steroid sulphatase in resistant prostate cancer cells »
Table of Contents: EAU 2020
Letter from the Editor
EAU 2020 Highlights Podcast
Surgical Techniques and Safety
The new adjustable artificial sphincter victo: Surgical technique and results after a follow-up of more than one year
New urosepsis data from the SERPENS study
Intra-operative cone-beam computed tomography for detecting residual stones in percutaneous nephrolithotomy
Pressure and temperature: do high-power lasers pose a threat?
Radiation stewardship for patient and endourologist
New lithotripter data: improved stone clearance
Beyond the limits of ultrasound: Three dimensional augmented reality robot assisted partial nephrectomy (3D AR-RAPN) for complex renal masses
Imaging guided surgery with augmented reality for robotic partial nephrectomy
KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib
Debate: upfront cytoreductive nephrectomy or not?
Robotic-assisted partial nephrectomy: lower morbidity
Reduced BCG frequency, faster NMIBC recurrence
Nadofaragene firadenovec effective in BCG-unresponsive papillary NMIBC
Understanding MIBC biology for novel treatment options
Prostate Cancer & Imaging
Transperineal laser ablation of prostate
Prostatectomy: R-LRPE better than LRPE for continence
PSMA PET-CT staging is 27% more accurate
Docetaxel + hormonal therapy: improved prostate cancer PFS
ARAMIS subgroup analysis: darolutamide benefits across PSADT groups
Large patient-driven survey reveals QoL issues after prostate cancer treatment
Targeting steroid sulphatase in resistant prostate cancer cells
Good tolerance of post-RP radiotherapy ± short-term ADT
BPH & LUTS
Minimizing post-operative stress urinary incontinence after HoLEP: Our preliminary experience and short-term results of ‘’En Bloc’’ technique with early apical release
LUTS 2-year outcomes: aquablation versus TURP
HoLEP versus PVP in prospective randomised trial
LUTS in the neuro-urologic patient
Testis Cancer & Andrology
Peyronie’s disease: surgical options
Infertility and testis cancer risk: causal or association?
32% more men complain of reduced sex drive in 2019 versus 2009
Best of EAU: Highlights on bladder cancer